# Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-paclitaxel-as-first-line-treatment-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shengxiang Ren,Jianhua Chen,Xingxiang Xu,Tao Jiang,Ying Cheng,Gongyan Chen,Yueyin Pan,Yong Fang,Qiming Wang,Yunchao Huang,Wenxiu Yao,Rui Wang,Xingya Li,Wei Zhang,Yanjun Zhang,Sheng Hu,Renhua Guo,Jianhua Shi,Zhiwu Wang,Peiguo Cao,Donglin Wang,Jian Fang,Hui Luo,Yi Geng,Chunyan Xing,Dongqing Lv,Yiping Zhang,Junyan Yu,Shundong Cang,Zeyu Yang,Wei Shi,Jianjun Zou,Caicun Zhou |
| Citations | 320 |
| DOI | 10.1016/j.jtho.2021.11.018 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4200204256 |
| PMID | 34923163 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Tao Jiang](https://scholariq.org/researchers/tao-jiang/)
- [Yueyin Pan](https://scholariq.org/researchers/yueyin-pan/)
- [Shundong Cang](https://scholariq.org/researchers/shundong-cang/)
- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.